Condition: Hematological Neoplasms · Sponsor: Wei Zhao
The investigators' purpose was to assess the feasibility of dosage individualization of the commonly used antineoplastic drugs and anti-infective drugs in children with hematoplastic disease.
This description comes directly from the study's public registry record.
Wei Zhao, Ph.D · 86053188383308 · zhao4wei2@hotmail.com
Yan H Shi, Ph.D · 86053188383308 · zhao4wei2@hotmail.com
Always discuss trial participation with your own doctor first.
| Department of Pediatrics, the Affiliated Hospital of Xuzhou Medical University | Xuzhou, Jiangsu, China | Completed |
| State Key Laboratory of Experimental Haematology, Department of Paediatric Haematology, Institute of Haematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College | Tanjin, Tianjin Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03844360